Most Recent
ASIC has launched a bid to gain access to legal advice provided by Ashurst to Australia and New Zealand Banking Group in the regulator's case over $35 million in allegedly illegal bank fees.
In a major blow to Australian businesses, the Full Federal Court has ruled that casual employees who work regular shifts are entitled to paid annual, personal and compassionate leave under the Fair Work Act.
Qantas employees who have been stood down due to the effects of the coronavirus pandemic are not entitled to access sick leave or compassionate leave, a court has ruled, with a union looking to appeal the decision.
The Virgin Australia administration continues to boost billables at the top end of town, with a short list of “well-funded” buyers revealed on Monday and an intense four weeks ahead as the bidders and their law firms scramble to make binding offers by the mid-June deadline.
Seven car makers defending class actions over defective Takata airbags have confirmed they will not be challenging a landmark decision that set aside a pre-settlement class closure order in the cases.
The ACCC has come up short in its appeal of a ruling that dismissed its challenge to Pacific National $205 million acquisition of Aurizon's Acacia Ridge Terminal in Queensland, with the Full Federal Court also releasing Pacific National from an undertaking given to the court.
An Ashurst partner is at risk of being evicted from his Point Piper home after allegedly refusing to pay a $150,000 special levy.
A former customer service manager for Qantas who claims to suffer from severe depression and anxiety has brought allegations of disability discrimination against Maurice Blackburn, claiming the law firm put pressure on her to settle her workers compensation case against the airline.
A law firm with a global footprint is facing a possible breach of trust lawsuit in relation to $27 million it held as security for costs in an international arbitration.
A court has dismissed a claim by the Australian Government for $325 million against pharmaceutical companies Sanofi and Bristol-Myers Squibb allegedly owed for excess subsidies it paid for blood-thinner Plavix as a result of an interlocutory injunction blocking a generic version of the blockbuster drug.